2019
DOI: 10.1007/s40290-019-00305-z
|View full text |Cite
|
Sign up to set email alerts
|

Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
13
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 15 publications
(13 citation statements)
references
References 131 publications
0
13
0
Order By: Relevance
“…A reliable biomarker that can accurately diagnose and stage NAFLD across the entire disease spectrum does not yet exist. 66,142,143 A diagnostic biomarker, in conjunction with a prognostic biomarker (of which some currently hold promise), would allow the identification of high-risk individuals on whom resources should be concentrated. A second challenge is the substantial heterogeneity of NAFLD and the current limited understanding of disease phenotypes.…”
Section: Challenges and Prospectsmentioning
confidence: 99%
“…A reliable biomarker that can accurately diagnose and stage NAFLD across the entire disease spectrum does not yet exist. 66,142,143 A diagnostic biomarker, in conjunction with a prognostic biomarker (of which some currently hold promise), would allow the identification of high-risk individuals on whom resources should be concentrated. A second challenge is the substantial heterogeneity of NAFLD and the current limited understanding of disease phenotypes.…”
Section: Challenges and Prospectsmentioning
confidence: 99%
“…
We read with interest the article by K•I Zheng et al [1], we congratulate the authors for their work and conclusions. Although the definition of obesity in this article is slightly different from the internationally accepted criteria, however, the authors had successfully used the data to answer the research question.Many studies had reported non-alcoholic fatty liver disease [NAFLD] and non-alcoholic steatohepatitis [NASH] in association with obesity [2][3][4][5]. These two conditions are not specific to the obese or overweight patients but also affecting non-obese population with risk of progression to cirrhosis, fibrosis and hepatocellular cancer [6].The NAFLD and NASH have been diagnosed frequently with liver biopsies, but also liver imaging cross sectional studies which were provided the diagnosis and the assessment of the disease progression.
…”
mentioning
confidence: 99%
“…Many studies had reported non-alcoholic fatty liver disease [NAFLD] and non-alcoholic steatohepatitis [NASH] in association with obesity [2][3][4][5]. These two conditions are not specific to the obese or overweight patients but also affecting non-obese population with risk of progression to cirrhosis, fibrosis and hepatocellular cancer [6].…”
mentioning
confidence: 99%
“…Ideal serological markers for noninvasive diagnosis of NAFLD do not yet exist. 31 Hence, the main goal of this study was to identify an indicator for predicting the incidence of NAFLD in a large population who underwent health examination.…”
Section: Discussionmentioning
confidence: 99%